BTL VANQUISH ME - OPERATOR’S MANUAL I PAGE 9 OF 44
•
Thermohyperesthesia (very acute thermoesthesia or temperature sense; exaggerated
perception of hot and cold).
•
Acute inflammations.
•
Severe arterial obstructions (stage III and IV).
•
Gynecological disorders involving acute inflammation.
•
Wetness, perspiration, or damp bandages.
•
Permeating irradiation of the thorax in cases of severe heart diseases (heart valve
diseases, myocardial insufficiency, myocardial infarct, severe coronary sclerosis).
•
Pregnancy, since irradiation could cause teratogenous damage due to alterations of
blood circulation and diffusion.
•
Menstruation.
•
Nursing.
•
Sudeck’s syndrome, stage I and II.
•
Basedow’s disease (irradiation could cause serious states of agitation).
•
Varicose veins (irradiation could cause congestive pain).
•
Cardiac conditions.
•
Deep vein thrombosis, phlebitis, varices.
•
Arterial disease, circulatory insufficiency.
•
Occlusive vascular disease, such as arteriosclerosis obliterans and thromboangitis
obliterans, in which organic occlusion and ischemia are evident.
•
Ischemic tissues in individuals with vascular disease where the blood supply would be
unable to follow the increase in metabolic demand and tissue necrosis might result.
BTL Vanquish ME must not be applied:
•
Over eyes, testes, head and neck.
•
Over the pelvic or low back area when an IUD is present.
•
Over cardiac pacemakers and defibrillators, cochlear implants, bone growth stimulators,
deep brain stimulators, spinal cord stimulators, and other nerve stimulators.
•
Over open lamina (after laminectomy; spina bifida).
•
Over superficial endoprosthesis or metal implants.
•
Directly over the carotid sinuses, cervical stellate ganglion, or vagus nerve located in the
anterior neck triangle.
•
Directly over cancerous tumors or lesions due to its potential to increase blood flow to the
area of malignancy.
•
Over neoplastic tissues or space occupying lesions.
•
In the presence of systemic or local infection (sepsis, osteomyelitis, tuberculosis) or if the
patient has an elevated temperature.
•
If there is a scar in or near the treatment area, check with the patient and/or the patient's
chart to determine if there is metal under the scar.
•
BTL Vanquish ME should not be applied over the uterus unless specific assurance can
be attained from the patient that she is not pregnant.
•
The device is cleared for patients 22 years and older and that safety and effectiveness
have not been established in pediatric patients or patients younger than 22 years.
